On May 8, 2019, Santhera joined Parent Project Muscular Dystrophy for a webinar to provide the community with an update about respiratory health in Duchenne muscular dystrophy and the ongoing SIDEROS clinical trial.
If you missed the live event, the recording can be found below.
Watch the Recording
About the presenters
- Thomas Meier, PhD
Chief Executive Officer
Thomas Meier was appointed Chief Executive Officer (CEO) of Santhera in October 2011, having served for 7 years as Chief Scientific Officer (CSO) for the company. Thomas was the founder and CEO of MyoContract, a Basel-based research company focused on orphan neuromuscular diseases, which he merged with Graffinity Pharmaceuticals of Heidelberg, Germany, in 2004, to form today’s Santhera. He received his PhD in biology from the University of Basel in Switzerland and subsequently joined the University of Colorado Health Sciences Center, Denver. He has a distinguished scientific track record in the field of neuromuscular research. Before joining the industry, Thomas was awarded the International Research Fellowship Award from the US National Institutes of Health (NIH) and a long-term fellowship from the Human Frontier Science Program./li>
- Kristina Nygren, MD
Chief Medical Officer
Kristina Sjöblom Nygren joined Santhera as Chief Medical Officer (CMO) and Head of Development and member of Santhera’s Executive Management Team in January, 2017. Kristina studied chemistry and biochemistry and graduated as a medical doctor from the Karolinska Institute, Sweden. She brings over 18 years of experience as biopharmaceutical executive in drug development across multiple therapeutic areas, including orphan diseases. During her career she has worked in clinical development roles at Wyeth, AstraZeneca and Biovitrum. Prior to joining Santhera Kristina served as VP and Head of Clinical Development at Sobi where she was leading the clinical development of all programs from first in man to commercialization and life cycle management.